Lilly's Lechleiter Talks Innovation During Obama's Consultation With CEOs
This article was originally published in The Pink Sheet Daily
Lilly's CEO was the sole representative of the biopharmaceutical industry participating in President Obama's meeting with the leaders of 20 large U.S. corporations.
You may also be interested in...
Lilly CEO John Lechleiter is urging policy makers to focus on the "I word" - Innovation - in the context of the health care reform debate
Heavily rebated drugs may already be meeting the price goals established by the Senate legislation. As a result, price negotiation for drugs covered under Part B are likely to yield greater savings to the Medicare program than Part D.
As legislation authorizing Medicare price 'negotiation' clears the Senate and appears on its way toward enactment after years of efforts by US congressional Democrats, and opposition by Republicans and the pharmaceutical industry, the bill continues to be tweaked.